-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Jan 2025 21:54 GMT
Geron Corporation (Nasdaq: GERN), a commercial … to continued employment with Geron through the applicable vesting dates … under the plan.
About Geron
Geron is a commercial-stage biopharmaceutical … the United States for the treatment of certain adult patients …
-
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
10 Jan 2025 12:30 GMT
… and Incyte’s Niktimvo and Geron’s Rytelo
NEW YORK, Jan … , Enhancing Prospects Since 2020, Royalty Pharma has announced transactions of approximately … companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio …
-
Myelodysplastic Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies By Delveinsight
27 Dec 2024 12:56 GMT
… , Eli Lilly and Company, Geron Corporation, Amgen, Astex Pharmaceuticals, Hoffmann-La Roche, Janssen … Syndrome market share @
Myelodysplastic Syndrome Treatment Market
Myelodysplastic Syndrome Market Strengths …
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Dec 2024 21:38 GMT
Geron Corporation (Nasdaq: GERN), a commercial … to continued employment with Geron through the applicable vesting dates … to new employees.
About Geron
Geron is a commercial-stage biopharmaceutical … the United States for the treatment of certain adult patients …
-
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
13 Dec 2024 12:43 GMT
Geron Corporation (Nasdaq: GERN), a … hematologic diseases and their treatment.
About Lower-Risk Myelodysplastic … having poorer prognosis. Current treatment options for those failing … Geron is successful in commercializing RYTELO (imetelstat) for the treatment …
-
Analyst Scoreboard: 4 Ratings For Geron
10 Dec 2024 13:25 GMT
… recent developments related to Geron. This information provides a …
Unveiling the Story Behind Geron
Geron Corp is a clinical-stage … and development of cancer treatments. The company' … is being tested for the treatment of myelodysplastic syndromes, which …
-
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
10 Dec 2024 14:20 GMT
Geron Corporation (Nasdaq: GERN), a … to evaluate the safety, pharmacokinetics (PK), and clinical activity … to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of … Geron is successful in commercializing RYTELO (imetelstat) for the treatment of …
-
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
10 Dec 2024 14:20 GMT
Geron Corporation (Nasdaq: GERN), a … clinical benefit from imetelstat treatment similar to that demonstrated … to receive imetelstat. Median treatment duration on imetelstat, including … Geron is successful in commercializing RYTELO (imetelstat) for the treatment …
-
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
27 Nov 2024 14:16 GMT
Geron Corporation (Nasdaq: GERN), a commercial-stage … Investors and Media section of Geron’s website under Events … period of 30 days.
About Geron
Geron is a commercial-stage biopharmaceutical … the United States for the treatment of certain adult patients with …
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Nov 2024 21:48 GMT
Geron Corporation (Nasdaq: GERN), a commercial … to continued employment with Geron through the applicable vesting dates … to new employees.
About Geron
Geron is a commercial-stage biopharmaceutical … the United States for the treatment of certain adult patients …
About
© 1995-2025